Patents Assigned to TEVA PHARMACEUTICALS PTY LTD
  • Combination of lenalidomide and polypeptide construct, and uses thereof
    Patent number: 10232041
    Abstract: Methods for cancer treatment include administering to a cancer patient an anti-CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: March 19, 2019
    Assignee: TEVA PHARMACEUTICALS PTY LTD
    Inventors: Sarah L. Pogue, David S. Wilson, Anthony Gerard Doyle, Collette Jane Behrens